
Nicole Erin Kinsey White
Examiner (ID: 18489, Phone: (571)272-9943 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1671, 1672, 1648 |
| Total Applications | 1130 |
| Issued Applications | 560 |
| Pending Applications | 136 |
| Abandoned Applications | 472 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20040932
[patent_doc_number] => 20250179154
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-05
[patent_title] => NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
[patent_app_type] => utility
[patent_app_number] => 19/035336
[patent_app_country] => US
[patent_app_date] => 2025-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42806
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19035336
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/035336 | NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE | Jan 22, 2025 | Issued |
Array
(
[id] => 20343138
[patent_doc_number] => 12466860
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-11
[patent_title] => Methods for using dual glycan binding AAV vectors
[patent_app_type] => utility
[patent_app_number] => 19/006818
[patent_app_country] => US
[patent_app_date] => 2024-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 15680
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19006818
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/006818 | Methods for using dual glycan binding AAV vectors | Dec 30, 2024 | Issued |
Array
(
[id] => 19982998
[patent_doc_number] => 20250121220
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => BETACORONAVIRUS mRNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 19/000377
[patent_app_country] => US
[patent_app_date] => 2024-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19000377
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/000377 | BETACORONAVIRUS mRNA VACCINES | Dec 22, 2024 | Pending |
Array
(
[id] => 19982999
[patent_doc_number] => 20250121221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => BETACORONA VIRUS mRNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 19/000472
[patent_app_country] => US
[patent_app_date] => 2024-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79484
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19000472
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/000472 | Betacorona virus mRNA vaccines | Dec 22, 2024 | Issued |
Array
(
[id] => 19961833
[patent_doc_number] => 12331321
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-06-17
[patent_title] => Alpha-herpesvirus insensitive monoclonal cell strain, and preparation method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/964018
[patent_app_country] => US
[patent_app_date] => 2024-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 19
[patent_no_of_words] => 0
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18964018
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/964018 | Alpha-herpesvirus insensitive monoclonal cell strain, and preparation method therefor and use thereof | Nov 28, 2024 | Issued |
Array
(
[id] => 19730301
[patent_doc_number] => 12208288
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-28
[patent_title] => Betacoronavirus RNA vaccines
[patent_app_type] => utility
[patent_app_number] => 18/762372
[patent_app_country] => US
[patent_app_date] => 2024-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 41
[patent_no_of_words] => 85519
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18762372
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/762372 | Betacoronavirus RNA vaccines | Jul 1, 2024 | Issued |
Array
(
[id] => 20212712
[patent_doc_number] => 12409347
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-09
[patent_title] => Betacoronavirus mRNA vaccines
[patent_app_type] => utility
[patent_app_number] => 18/762296
[patent_app_country] => US
[patent_app_date] => 2024-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 41
[patent_no_of_words] => 81605
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18762296
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/762296 | Betacoronavirus mRNA vaccines | Jul 1, 2024 | Issued |
Array
(
[id] => 19554957
[patent_doc_number] => 20240366749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => COMBINATION HMPV/RSV RNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 18/762384
[patent_app_country] => US
[patent_app_date] => 2024-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85448
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18762384
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/762384 | Betacoronavirus RNA vaccines | Jul 1, 2024 | Issued |
Array
(
[id] => 19624112
[patent_doc_number] => 12162916
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-10
[patent_title] => Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (ASC) and methods of use
[patent_app_type] => utility
[patent_app_number] => 18/637070
[patent_app_country] => US
[patent_app_date] => 2024-04-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 12892
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637070
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/637070 | Compositions targeting apoptosis-associated speck-like protein with caspase activation and recruitment domain (ASC) and methods of use | Apr 15, 2024 | Issued |
Array
(
[id] => 19755721
[patent_doc_number] => 20250044286
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-06
[patent_title] => SOLUTION-BASED PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS USING METALLIC NANOSTRUCTURES
[patent_app_type] => utility
[patent_app_number] => 18/605728
[patent_app_country] => US
[patent_app_date] => 2024-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16054
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18605728
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/605728 | SOLUTION-BASED PLASMONIC SPECIFIC-BINDING PARTNER ASSAYS USING METALLIC NANOSTRUCTURES | Mar 13, 2024 | Pending |
Array
(
[id] => 19265627
[patent_doc_number] => 20240209326
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => BACTERIAL DELIVERY VEHICLE, PROCESS OF PRODUCTION AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/598495
[patent_app_country] => US
[patent_app_date] => 2024-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18598495
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/598495 | BACTERIAL DELIVERY VEHICLE, PROCESS OF PRODUCTION AND USES THEREOF | Mar 6, 2024 | Pending |
Array
(
[id] => 19232228
[patent_doc_number] => 20240189419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/583389
[patent_app_country] => US
[patent_app_date] => 2024-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4633
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583389
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/583389 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF CORONAVIRUS INFECTION USING AN IMMUNOMODULATOR AND VACCINE COMPOSITIONS COMPRISING THE SAME | Feb 20, 2024 | Pending |
Array
(
[id] => 19170983
[patent_doc_number] => 20240156957
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENIFYING AGENTS THAT MODULATE MYC
[patent_app_type] => utility
[patent_app_number] => 18/423395
[patent_app_country] => US
[patent_app_date] => 2024-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18423395
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/423395 | Methods for reducing anergy in lymphocytes using modulators of MYC | Jan 25, 2024 | Issued |
Array
(
[id] => 19479822
[patent_doc_number] => 20240327864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => DIAPHRAGM-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/417465
[patent_app_country] => US
[patent_app_date] => 2024-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25576
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417465
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/417465 | DIAPHRAGM-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF | Jan 18, 2024 | Pending |
Array
(
[id] => 19722793
[patent_doc_number] => 20250025544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => IMMUNE CHECKPOINT INHIBITOR CO-EXPRESSION VECTORS
[patent_app_type] => utility
[patent_app_number] => 18/404681
[patent_app_country] => US
[patent_app_date] => 2024-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64318
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 255
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18404681
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/404681 | IMMUNE CHECKPOINT INHIBITOR CO-EXPRESSION VECTORS | Jan 3, 2024 | Pending |
Array
(
[id] => 19316866
[patent_doc_number] => 20240238406
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-18
[patent_title] => HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 18/540621
[patent_app_country] => US
[patent_app_date] => 2023-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35547
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540621
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/540621 | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY | Dec 13, 2023 | Pending |
Array
(
[id] => 19496508
[patent_doc_number] => 20240335526
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => COMBINATION HMPV/RSV RNA VACCINES
[patent_app_type] => utility
[patent_app_number] => 18/528323
[patent_app_country] => US
[patent_app_date] => 2023-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85424
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528323
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/528323 | Betacoronavirus MRNA vaccines | Dec 3, 2023 | Issued |
Array
(
[id] => 19300412
[patent_doc_number] => 20240228981
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => ATTENUATED VIRUSES USEFUL FOR VACCINES
[patent_app_type] => utility
[patent_app_number] => 18/512196
[patent_app_country] => US
[patent_app_date] => 2023-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50089
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512196
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/512196 | ATTENUATED VIRUSES USEFUL FOR VACCINES | Nov 16, 2023 | Pending |
Array
(
[id] => 19449270
[patent_doc_number] => 20240309400
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => VECTORS
[patent_app_type] => utility
[patent_app_number] => 18/504554
[patent_app_country] => US
[patent_app_date] => 2023-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504554
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/504554 | VECTORS | Nov 7, 2023 | Pending |
Array
(
[id] => 19674551
[patent_doc_number] => 12186389
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Nucleic acid base vaccine against emerging SARS-CoV-2 variants
[patent_app_type] => utility
[patent_app_number] => 18/494893
[patent_app_country] => US
[patent_app_date] => 2023-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 154231
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18494893
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/494893 | Nucleic acid base vaccine against emerging SARS-CoV-2 variants | Oct 25, 2023 | Issued |